Heartbeam (BEAT) Q2 2024 earnings summary

Executive summary

• AIMIGO, a credit card-sized, cable-free 12-lead ECG device, is under active FDA review with a limited launch targeted by year-end 2024; a second 510(k) for 12-lead synthesis software is in preparation.

• The technology leverages proprietary vector and VECG technology with advanced AI for arrhythmia detection, showing superior performance to expert panels and single-lead ECG; future plans include heart attack detection and chronic disease monitoring.

• Clinical studies, including the 198-patient VALID-ECG trial and an 80-patient pilot, support diagnostic capabilities, with over 500 patients and 7,500+ recordings demonstrating equivalence to traditional 12-lead ECG.

• No material commercial revenue is expected in 2024; continued operations depend on raising additional capital or strategic partnerships.

• Company received industry recognition, including a MedTech Breakthrough Award and Russell Microcap Index inclusion.

Financial highlights

• Q2 2024 net loss was $5.0 million, up from $3.2 million in Q2 2023; operating expenses rose to $5.1 million, driven by higher R&D and G&A costs.

• Research and development expenses increased to $2.8 million from $1.5 million year-over-year.

• General and administrative expenses rose to $2.2 million from $1.8 million year-over-year.

• Cash and cash equivalents were $9.2 million as of June 30, 2024, down from $16.2 million at year-end 2023.

• Net cash used in operating activities for the first half of 2024 was $7.0 million.

Outlook and guidance

• Anticipates FDA clearance and a limited AIMIGO launch by end of 2024, with feedback to inform broader rollout.

• Preparing a second FDA 510(k) submission for the 12-lead synthesis algorithm after AIMIGO clearance.

• No significant commercial revenue is expected in 2024; future operations depend on additional capital or partnerships.

• Focus remains on arrhythmia detection initially, with heart attack detection and chronic disease monitoring as future milestones.

• Existing cash is insufficient to fund operations for the next twelve months, raising substantial doubt about going concern.